Journal Article
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Barbara-Burnham, L., and Young, L. S.,
“Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.”,
Antimicrobial agents and chemotherapy, vol. 40, no. 3, pp. 546-51, 1996.
L. E. Bermudez, Kolonoski, P., Young, L. S., and Inderlied, C. B.,
“Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 8, pp. 1844-8, 1994.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S.,
“Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.”,
Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.
L. E. Bermudez, Petrofsky, M., Kolonoski, P., and Young, L. S.,
“An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract.”,
The Journal of infectious diseases, vol. 165, no. 1, pp. 75-9, 1992.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., and Young, L. S.,
“Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 12, pp. 2717-21, 1994.
L. E. Bermudez, Petrofsky, M., Kolonoski, P., and Young, L. S.,
“Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.”,
Antimicrobial agents and chemotherapy, vol. 42, no. 1, pp. 180-3, 1998.
H. S. Wu, Kolonoski, P., Chang, Y. Y., and Bermudez, L. E.,
“Invasion of the brain and chronic central nervous system infection after systemic Mycobacterium avium complex infection in mice.”,
Infection and immunity, vol. 68, no. 5, pp. 2979-84, 2000.
L. E. Bermudez, Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., and Young, L. S.,
“Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.”,
Antimicrobial agents and chemotherapy, vol. 43, no. 8, pp. 1870-4, 1999.
F. J. Sangari, Goodman, J., Petrofsky, M., Kolonoski, P., and Bermudez, L. E.,
“Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes.”,
Infection and immunity, vol. 69, no. 3, pp. 1515-20, 2001.
L. E. Bermudez, Kolonoski, P., and Young, L. S.,
“Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model.”,
Journal of leukocyte biology, vol. 47, no. 2, pp. 135-41, 1990.
L. E. Bermudez, Martinelli, J., Petrofsky, M., Kolonoski, P., and Young, L. S.,
“Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model.”,
The Journal of infectious diseases, vol. 169, no. 3, pp. 575-80, 1994.
L. E. Bermudez, Kolonoski, P., and Young, L. S.,
“Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.”,
Antimicrobial agents and chemotherapy, vol. 40, no. 4, pp. 1033-5, 1996.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P., and Young, L. S.,
“Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.”,
Antimicrobial agents and chemotherapy, vol. 45, no. 8, pp. 2210-4, 2001.
L. E. Bermudez, Stevens, P., Kolonoski, P., Wu, M., and Young, L. S.,
“Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor.”,
Journal of immunology (Baltimore, Md. : 1950), vol. 143, no. 9, pp. 2996-3000, 1989.